A Simple “New” Method to Accelerate Clearance of Carbon Monoxide

AKINORI TAKEUCHI, ALEX VESELY, JOSHUA RUCKER, LEEOR Z. SOMMER, JANET TESLER, ELANA LAVINE, ARTHUR S. SLUTSKY, WOLFGANG H. MALECK, GEORGE VOLGYESI, LUDWIK FEDORKO, STEVE ISCOE, and JOSEPH A. FISHER

Department of Anaesthesia, University Health Network, University of Toronto, and Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto; Department of Physiology, Queens University, Kingston, Ontario, Canada; Department of Anesthesiology and Resuscitology, Nagoya City University Medical School, Nagoya, Japan; and Department of Anesthesia, Klinikum, Ludwigshafen, Germany

The currently recommended prehospital treatment for carbon monoxide (CO) poisoning is administration of 100% O₂. We have shown in dogs that normocapnic hyperpnea with O₂ further accelerates CO elimination. The purpose of this study was to examine the relation between minute ventilation (Ve) and the rate of elimination of CO in humans. Seven healthy male volunteers were exposed to CO (400 to 1,000 ppm) in air until their carboxyhemoglobin (COHb) levels reached 10 to 12%. They then breathed either 100% O₂ at resting Ve (4.3 to 9.0 L min⁻¹) for 60 min or O₂ containing 4.5 to 4.8% CO₂ (to maintain normocapnia) at two to six times resting Ve for 90 min. The half-time of the decrease in COHb fell from 78 ± 24 min (mean ± SD) during resting Ve with 100% O₂ to 31 ± 6 min (p < 0.001) during normocapnic hyperpnea with O₂. The relation between Ve and the half-time of COHb reduction approximated a rectangular hyperbola. Because both the method and circuit are simple, this approach may enhance the first-aid treatment of CO poisoning.

Carbon monoxide (CO) inhalation is the leading cause of fatal poisoning in the industrialized world (1). CO decreases the delivery of O₂ to the tissues by displacing O₂ from hemoglobin and forming carboxyhemoglobin (COHb). Primary treatment of CO poisoning consists of administration of 100% O₂ to increase dissolved O₂ in the plasma and displace CO from the O₂-binding sites on hemoglobin (Hb), thus restoring O₂ delivery to tissues. In cases of severe CO poisoning, the only additional therapy available is hyperbaric O₂. Unfortunately, hyperbaric chambers are unsuitable for emergency treatment, since they are relatively uncommon; for example, there are 340 hyperbaric chambers in the United States (2) and about 8 National Health Service facilities in the United Kingdom (3). Even in locations where hyperbaric chambers are available, delays in initiating therapy are inevitable because of the time needed to transport the patient, assemble trained personnel, and set up the chamber.

As early as 1922, CO₂-induced hyperpnea was shown to be effective in treating CO poisoning (4–6). Implementing the hyperpnea was problematic. Hyperpnea driven by fixed inspired concentrations of CO₂ of 5 to 10% was uncomfortable for conscious patients. Conversely, simple voluntary hyperventilation with 100% O₂ is inappropriate since it causes respiratory alkalosis, which in turn decreases cerebral blood flow and increases the affinity of Hb for O₂, both of which may aggravate brain hypoxia. This dilemma has been addressed by the recent development of a nonrebreathing circuit (7) that passively maintains normocapnia regardless of increases in minute ventilation (Ve). Fisher and colleagues (1) established the feasibility of using the circuit to accelerate CO elimination in a dog model, in which increases in Ve to six times control values shortened the half-time of reduction of COHb (t½) to less than half that at control Ve.

Although the predicted relation between Ve and the rate of CO elimination during breathing of 20% O₂ is approximately that of a rectangular hyperbola (6), the actual relation, including that during breathing of 100% O₂, has not yet been determined. Therefore, the primary aim of the present study with humans was to examine the relation between Ve and the rate of COHb reduction during breathing of 100% O₂ and during normocapnic hyperoxic hyperpnea. We also wanted to determine whether hyperpnea could be sustained long enough to result in a clinically significant decrease in COHb.

METHODS

Subjects

After receiving approval from the Institutional Review Board of the University of Toronto and obtaining written informed consent, we studied seven healthy male volunteers from the hospital medical and scientific staff. All had normal pulmonary function, including CO diffusion capacity and Hb concentrations (Table 1). Only males were studied, in order to avoid the need for a larger cohort to account for an expected sex-related difference in the rate of CO elimination (8).

Principle of Technique

Our technique for maintaining normocapnia during hyperpnea is based on the following two principles, as described in detail by Sommer and colleagues (7): (1) the rate of CO₂ elimination is determined by the flow of “fresh gas” (not containing CO₂) to the alveoli; and (2) any Ve exceeding this flow of fresh gas will not affect Pao₂ if the additional inspired gas contains CO₂ at a partial pressure equal to that in the subject’s mixed venous blood. Thus, hyperpnea with this technique does not increase the partial pressure gradient for CO₂ between pulmonary capillary blood and alveolar gas, but does increase the gradient for all other gases, including CO and O₂.

Our circuit (Figure 1) consisted of a face mask attached through a low-resistance heat and moisture exchanger to a large-bore nonrebreathing valve. The valve was connected to a 7-L water spirometer, which served as a fresh gas reservoir. During each phase of the experiment, inspired (fresh) gas was continually replenished at a fixed flow. An adjustable positive end-expiratory pressure (PEEP) valve, set at 2 cm H₂O and placed between the spirometer and the nonrebreathing valve, ensured that the inspired gas filled the spirometer during expiration. Resting (control) Ve was determined from a flowmeter adjusted so that the reservoir just emptied at the end of each inspiration, an indication that this flow of fresh gas exactly matched the subject’s Ve. The reserve gas consisted of 6% CO₂ in O₂, the net inspired CO₂ concentration depending on the Ve.

(Received in original form July 12, 1999 and in revised form October 4, 1999)

Supported by the Toronto Health Network Department of Anaesthesia and the Nusbaum Family Foundation.

Correspondence and requests for reprints should be addressed to Dr. Joseph A. Fisher, Department of Anaesthesia, The Toronto Hospital-General Division, Toronto, ON, M5G 2C4 Canada. E-mail: Joe.fisher@utoronto.ca

Internet address: www.atsjournals.org
Protocol

Subjects were seated comfortably and breathed room air through the circuit for 5 to 10 min to allow them to accommodate to the face mask, and to allow measurement of their resting $V_e$ with room air. Subjects were randomly assigned to one of the two “treatments” (described subsequently) and were then exposed to 400 to 1,000 ppm CO in air. Blood, sampled every 5 min from an indwelling 20-gauge intravenous cannula, was analyzed photometrically for COHb (OSM 3; Radiometer AS, Copenhagen, Denmark). After COHb reached 10 to 12%, subjects were either: (1) treated with 100% O2 at resting $V_e$ for 60 min (control); or (2) were subjected to normocapnic hyperoxic hyperpnea, during which time they were instructed to maintain a constant pattern of breathing. After 60 min of treatment, subjects maintained flow of 400 ml/min. The CO concentration was measured with an infrared capnometer (Ametek Inc., Pittsburgh, PA) and corrected for $P_{O_2}$. Data were recorded with commercial electronic data acquisition software (WIN D A Q/200; DATA Q Instruments, Inc., Akron OH).

Data Collection

We monitored blood pressure and $O_2$ saturation noninvasively (AS/3; Datex, Helsinki, Finland). Gas was sampled from the face mask at a flow of 400 ml/min. The CO2 concentration was measured with an interfered capnometer. Values of $t_{1/2}$ were calculated as $(\ln 2)/t_{1/2}$. To facilitate pooling of the $t_{1/2}$ and $V_e$ data from all subjects, we normalized the latter for estimated variations in body Hb content.

Results

There was no difference in COHb levels before the two treatments ($p = 0.39$). COHb decreased exponentially during both treatments (Figure 2). During resting $V_e$ with 100% $O_2$ ($7.1 \pm 2.6$ L/min), $t_{1/2}$ was $78 \pm 24$ min. Normocapnic hyperpnea decreased $t_{1/2}$, the decrease depending on the degree of hyperpnea (Figure 3). After 60 min, COHb levels decreased from 10.6 ± 0.4% to 6.2 ± 1.1% in subjects breathing 100% $O_2$, and from 11.0 ± 0.9% to 3.0 ± 1.0% during normocapnic hyper-
pnea; COHb levels after treatment with normocapnic hyperoxic hyperpnea were significantly less than those after treatment with 100% O2 (p < 0.0001, paired t test). During hyperpnea, the PETCO2 and the rate × pressure product (an index of myocardial O2 consumption [10]) did not differ from those obtained at rest (breathing air or room air plus CO). All subjects maintained hyperpnea for 90 min without difficulty. As compared with ventilation with room air (without and with CO), subjects breathing 100% O2 spontaneously (without control of PETCO2) had a greater VE (7.1 ± 2.6 L/min versus 5.6 ± 1.5 L/min, p < 0.05) and lower PETCO2 (39.4 ± 3.1 mm Hg versus 42.2 ± 2.1 mm Hg, p < 0.05). None of the subjects was aware of his increased VE.

DISCUSSION

In our subjects, moderate normocapnic hyperoxic, hyperpnea accelerated the clearance of CO as compared with that during control VE with 100% O2. The t1/2 decreased in a hyperbolic fashion as VE increased. Our subjects were able to sustain a VE up to six times greater than their resting levels with room air for at least 90 min, a time sufficient to reduce initial levels of COHb by about 85%.

Investigators had earlier noted that both dogs and human patients respond to severe poisoning with coal gas (containing about 30% CO) with hyperventilation followed by hyperventilation (4) (see also Figure 10 in Norman and Ledingham [11]). This hyperventilation was the limiting factor in treating CO-poisoned patients with 100% O2, the only known remedy at the time. Carbogen (95% O2, 5% CO2) was introduced in 1922 by Henderson and Haggard (12) for overcoming the secondary hyperventilation characteristic of CO poisoning. However, its use declined and it was eventually abandoned for this purpose as a result of the following three developments. The first was the introduction, after World War II, of a practical means of mechanical ventilation. The second was the submission of a report to the Medical Research Council (UK) (13) citing such complications as exacerbation of metabolic acidosis and post-exposure shock. In its stead, the authors recommended the use of pure O2 and, if necessary, mechanical ventilation in patients in respiratory failure. A third, in 1960, Smith and Sharp (14) reported the first successful treatment of CO-poisoned patients with hyperbaric O2. This became the preferred treatment for severe CO poisoning (2, 15, 16), resulting in the complete abandonment of carbogen for this purpose since about 1970.

Discontinuing the use of carbogen to treat hyperventilation may have been reasonable, but we suggest that abandoning hyperpnea for the treatment of CO poisoning was premature. One could reason that hyperpnea without CO2 added to the inspirate is not a viable treatment option, since it risks hyperventilation, which increases the affinity of Hb for O2 and significantly decreases cerebral blood flow (17), both of which decrease O2 delivery to the brain. On the other hand, using carbogen as the inspired gas prevents hyperventilation, but risks hyperventilation and respiratory distress and, as discussed earlier, has been associated with a number of other undesirable effects. In contrast, the circuit of Sommer and colleagues (7) simultaneously and passively minimizes any change in PACO2 regardless of VE, and accelerates CO elimination by widening the blood-alveolar gradient for CO.

Therapeutic Implications

Several factors should be considered in evaluating the potential of normocapnic hyperoxic hyperpnea for the first-aid treatment of CO poisoning. First, would it be effective in patients with very high levels of COHb? For ethical reasons, we limited COHb levels in our subjects to 10 to 12%, or about the same levels as found in heavy smokers, but much less than would result from severe CO poisoning. Nevertheless, our approach should be equally effective at higher COHb levels, because the distribution of CO between blood and tissues is approximately constant over the range of 0 to 60% COHb (18), and because the same principles governing CO elimination apply. Indeed, at higher COHb levels, normocapnic hyperpnea should actually be more effective in terms of the absolute volume of CO eliminated per unit time. As compared with breathing 100% O2 at resting VE, normocapnic hyperpnea approximately tripled the rate of reduction of COHb (Figure 3), thus providing about the same benefit as that obtained with hyperbaric O2 therapy (1, 8).

Second, can normocapnic hyperoxic hyperpnea be used in patients unwilling or unable to generate the required increases in VE? The results shown in Figure 3 suggest that even a modest increase in VE will produce a marked decrease in t1/2, particularly in patients with an initially low VE. Thus, a VE as low as 200 mL/min/kg (14 L/min in a 70 kg patient) should provide most of the benefit available from hyperpnea. Our subjects were able to sustain up to three times this VE for 90 min, a time sufficient to decrease COHb by 85%. In unconscious patients requiring manual ventilation, normocapnia can be maintained while increasing VE by attaching the reserve gas limb of the circuit of Sommer and colleagues (7) to the intake manifold of the self-inflating bag.

Even if no voluntary hyperpnea is planned, it may be prudent to maintain normocapnia when providing 100% O2 to all patients with CO poisoning. In our study, subjects breathing 100% O2 had a decrease in their PETCO2 of 2.9 mm Hg (range: 0 to 5.0 mm Hg) as compared with that when breathing air. If cerebrovascular reactivity to CO2 is retained during CO poisoning, cerebral blood flow and O2 delivery could fall by an average of 7% (17). By preventing hyperventilation, not only would cerebral blood flow be maintained (19), but there would be an even greater involuntary increase in VE (20), which would help eliminate CO. Furthermore, there would be no risk to patients as a result of maintaining normocapnia.

Third, would early treatment affect the prognosis in CO poisoning? Assuming that the mechanism of toxicity of CO includes a direct intracellular effect (21, 22) in addition to that due to hypoxemia, three factors—duration of exposure to CO ("soaking period"), COHb levels, and duration of tissue hyp-
oxia—will determine the extent of tissue injury. The delay in equilibration of CO between blood and tissues (9), and between the blood of the mother and fetus during pregnancy (23), implies that during exposure to lethal levels of CO there is always a gradient between blood and tissue Pco. Indeed, this gradient favoring continued entry of CO into tissues (9) and fetal blood (23) persists for at least 30 min after initiation of treatment with 100% O₂, and for even longer with air (9). Early maximally effective treatment would not only lower the gradient favoring continued entry of CO into tissues (9) and fetal blood (23), but would also provide the additional benefit of minimizing the peak tissue and fetal CO load (23).

Conclusions

Normocapnic hyperoxic hyperpnea increased the rate of elimination of CO in human subjects by two to three times that with normal breathing of 100% O₂, the current prehospital treatment for CO poisoning. With appropriate preparation, this technique can be applied at the time of rescue with a portable circuit. Provision of more rapid CO elimination earlier in the course of treatment for CO poisoning may improve the prognosis for this, the most common cause of poisoning.

References